Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HD CD19 CAR-T in relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
ChiCTR2300075912Phase 2Not yet recruiting
- Sponsor
- Changhai Hospital Department of Hematology
- Start
- Jul 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of HD CD19 CAR-T in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 2 more, sponsored by Changhai Hospital Department of Hematology. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
HD CD19 CAR-T
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)primary mediastinal large B-cell lymphoma (PMBCL)large-cell lymphoma
Beyond the preview
Go deeper on ChiCTR2300075912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075912.